P. LoRusso

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Gary K. Schwartz, P. LoRusso, Mark A. Dickson et al. · British Journal of Cancer · 2011 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).

D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak et al. · Journal of Clinical Oncology · 2011 · 135 citations

Medicine, Oncology, Pharmacology +16

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Braña, P. LoRusso, José Baselga et al. · Journal of Clinical Oncology · 2010 · 51 citations

Medicine, Oncology, Pharmacology +9

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

Geoffrey I. Shapiro, P. LoRusso, E. L. Kwak et al. · Journal of Clinical Oncology · 2011 · 44 citations

Medicine, Oncology, Pharmacology +16

Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline)

Brenda J. Foster, Lynne A. Jones, Richard Wiegand et al. · Investigational New Drugs · 1997 · 15 citations

Medicine, Pharmacokinetics, Pharmacology +10